Checkpoint Therapeutics is a clinical-stage immunotherapy and targeted oncology company focused on the treatments for patients with solid tumor cancers. Co. is evaluating its primary antibody product candidate, cosibelimab, an anti-programmed death-ligand 1 antibody. In addition, Co. is evaluating its primary small-molecule, targeted anti-cancer agent, CK-101, an epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer. Co, has a collaboration agreements with TG Therapeutics, Inc., to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The CKPT stock yearly return is shown above.
The yearly return on the CKPT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CKPT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|